Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|July 23, 2018
How Can Specialty Pharmacies Prepare for New Orphan Drugs?
Joy Gilbert, vice president of operations at US Bioservices, gives advice about how specialty pharmacies need to prepare for new drug approvals.
Advertisement
Joy Gilbert, vice president of operations at US Bioservices, a part of AmerisourceBergen, gives advice about how specialty pharmacies need to prepare for new drug approvals.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Baseline Interferon Activity in Monocytes Predicts mRNA Vaccine Adverse Effects, Study Finds
5